Full-Time
Senior Clinical Trial Manager
Updated on 5/14/2026
Janux Therapeutics
51-200 employees
Clinical-stage biotech developing tumor-activated immunotherapies
Compensation Overview
$134k - $170k/yr
San Diego, CA, USA
Hybrid
Hybrid role based in San Diego; remote allowed with approval; travel up to 25% for meetings/site visits.
 Biology & Biotech (1) |
|---|
- Bachelor’s degree with at least 5 years of hands-on clinical trial experience, within a pharmaceutical or biotech environment. A combination of CRO and sponsor-side experience will be considered.
- Demonstrated experience in oncology trials, including trial set-up, monitoring, and close-out.
- Global clinical trial management experience, especially in the European Union, highly desirable.
- Strong working knowledge of ICH/GCP regulations.
- Proficiency with electronic systems such as eClinical TMF, CTMS, Electronic Data Capture, etc.
- Ability to work independently and thrive in a collaborative team environment.
- Strong critical thinking skills, a sense of urgency, and a proactive problem-solving mindset.
- Excellent interpersonal, written, and verbal communication skills.
- Proficiency in Microsoft Office and comfort with technology.
- Minimal travel required (0 to 5%).
- Lead the successful execution of clinical trials from protocol concept to clinical study reports in support of complex oncology programs.
- Ensure inspection readiness by maintaining comprehensive study documentation and files.
- Organize and lead study and departmental meetings, including minute-taking and document archiving.
- Coordinate clinical trial equipment, supplies, and cross-functional project activities (e.g., Clinical Data Review Meetings).
- Ensure team compliance with study-specific training and perform TMF reviews for completeness.
- Support clinical sites in audit and inspection preparation.
- Assist with budget management and daily clinical operations, ensuring adherence to SOPs, ICH/GCP, and regulatory requirements.
- Monitor subject and site activity/metrics and perform quality checks across study components.
- Proactively identify, troubleshoot, and escalate issues impacting deliverables.
- Contribute to study set-up activities including protocol/synopsis development, informed consent forms, system configuration (CTMS, IRT), regulatory submissions, and operational documentation.
- Collaborate with CROs to ensure timely collection and archiving of TMF documents.
- Partner with regulatory affairs on essential document submissions.
- Support study close-out activities including TMF and drug reconciliation and CSR readiness.
- Foster effective communication and collaboration with study team members, Clinical Trial Managers, and Asset Leads.
- Participate in process improvement and quality initiatives related to study execution.
- Other duties as deemed necessary.
Janux Therapeutics develops cancer immunotherapies that activate the immune system inside tumors to attack cancer while sparing healthy tissue. Its products are tumor-activated and use a proprietary platform masking technology to reduce toxic side effects and improve efficacy compared with traditional T cell engagers. The company advances drug candidates through clinical trials, aiming for regulatory approval and eventual commercialization, with revenue expected from partnerships, licensing, and the sale of approved therapies. Its lead program JANX007 is being evaluated in a Phase 1 trial (ENGAGER PSMA 01) for metastatic prostate cancer to assess safety and preliminary effectiveness.
Company Size
51-200
Company Stage
IPO
Headquarters
San Diego, California
Founded
2017
Simplify's Take
What believers are saying
- $956M cash as of March 2026 funds JANX007 Phase 1b and JANX014 dosing through 2028.
- Bristol Myers Squibb $850M deal yields $35M milestone for solid tumor TRACTr in 2026.
- William Go's Kite Pharma experience accelerates JANX007 combos with darolutamide by H2 2026.
What critics are saying
- JANX008 discontinuation exposes TRACTr flaws in EGFR autoimmune trials, April 2026.
- JANX007 30% response rate trails Pluvicto, stalling Phase 2 in taxane-naïve mCRPC by 2027.
- Grade 3+ CRS in 6% of JANX007 patients triggers FDA hold on PSMA expansion, Q3 2026.
What makes Janux Therapeutics unique
- TRACTr platform masks T-cell engagers for tumor-selective activation, minimizing systemic toxicity.
- Proprietary PSMA-targeted JANX007 achieves 7.9-8.9 month rPFS in mCRPC with Grade 1-2 CRS.
- Double-masked JANX014 and CD28 TRACIr JANX013 expand PSMA franchise beyond conventional TCEs.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Janux Therapeutics who can refer or advise you
Benefits
401(k) Retirement Plan
401(k) Company Match
Health Insurance
Dental Insurance
Vision Insurance
Flexible Work Hours
Flexible Vacation
Relocation Assistance
Life Insurance
Supplemental disability insurance plans
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Janux Therapeutics, a clinical-stage biopharmaceutical company, has appointed William Go as Chief Medical Officer, effective 26 January 2026. Dr Go succeeds Zachariah McIver, who is leaving to pursue other opportunities. Dr Go brings over 20 years of haematology and oncology experience, having led programmes from early development through regulatory approvals and launches. Most recently, he served as Chief Medical Officer at A2 Biotherapeutics, where he initiated three Phase 1 clinical trials. Previously at Kite Pharma, he led the pivotal ZUMA-1 trial supporting FDA and EMA approvals of YESCARTA, the first CAR T-cell therapy approved for large B-cell lymphoma. Janux is advancing a pipeline of immunotherapies including two clinical-stage candidates targeting PSMA and EGFR for various cancers.
Janux Therapeutics taps dr. William Go as Chief Medical Officer. Go brings more than 20 years of hematology and oncology experience. Janux Therapeutics Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel immunotherapies, has appointed William Go, M.D., Ph.D., as its Chief Medical Officer (CMO). Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving the company to pursue other opportunities. "Janux is entering an important new phase as our programs advance and the complexity of our clinical and regulatory efforts increases," said David Campbell, Ph.D., President and CEO of Janux Therapeutics. "Will brings a combination of early- and late-stage development experience, regulatory leadership, and launch execution that will strengthen our organization as we scale." Go brings more than 20 years of hematology and oncology experience, leading programs from early clinical development through pivotal trials, global regulatory approvals, and first-in-class launches. He joins Janux at an important stage as the company advances its pipeline and continues to scale its clinical and regulatory operations. Most recently, Go served as Chief Medical Officer at A2 Biotherapeutics, where he led development of logic-gated CAR T-cell therapies for solid tumors. Previously, he held senior leadership roles at Kite Pharma, where he led the pivotal ZUMA-1 trial supporting the FDA and EMA approvals of YESCARTA. Following Kite's acquisition by Gilead Sciences, he continued in a senior clinical development leadership role overseeing programs in large B-cell lymphoma. Earlier in his career at Amgen, Go contributed to the global label expansion of Vectibix and helped advance extended RAS next-generation sequencing strategies in colorectal cancer to identify predictive biomarkers. Go earned a B.A. in Biology from Carleton College and completed an M.D. and Ph.D. through the UC San Diego Medical Scientist Training Program. He completed residency training in internal medicine and a fellowship in hematology/oncology at UC San Diego, with tumor immunology research supported by fellowships from the California Institute for Regenerative Medicine and the American Association of Cancer Institutes. "What attracts me to Janux is the strength of its science and the breadth and depth of its oncology pipeline, anchored by a differentiated, tumor-activated T-cell engager platform," Go said. "Janux is tackling important clinical challenges with programs designed to build on existing standards of care, and I believe the company is well positioned to deliver meaningful advances for patients. I'm excited to work with the Janux team, investigators, and partners as we move these programs forward." More Janux news. Janux Therapeutics and Bristol Myers Squibb (BMS) announced recently that they will develop a novel, tumor-activated therapeutic in an exclusive worldwide licensing agreement.
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug. Jan 22 (Reuters) - Janux Therapeutics said on Thursday it has entered a collaboration with Bristol Myers Squibb to develop a new cancer treatment, sending its shares up more than 12% in premarket trading. The therapy is intended to treat "solid tumors" - meaning cancers that form masses in organs such as the lung, breast, colon or pancreas, Janux said, and it will target a tumor marker found across several types of cancers. Janux may get up to $50 million in upfront and near-term milestone payments under the agreement, and could earn additional payments totaling about $800 million tied to progress in development, regulatory approvals and sales. It would also get royalties on worldwide product sales if a drug reaches the market. "This collaboration marks a significant milestone for Janux," Janux CEO David Campbell said in a statement, adding that the partnership pairs the company's technology with Bristol Myers' development and commercialization capabilities. Janux will complete preclinical testing and hand over clinical testing to Bristol. Bristol will then take up subsequent development and global commercialization of the drug, with Janux remaining actively involved through completion of the early-stage study.
Janux posts Phase 1 data for psma-directed TCE in mCRPC. San Diego-based biotech Janux Therapeutics released updated interim data from its Phase 1 clinical trial of JANX007, a first-in-class, PSMA-targeted T-cell engager developed on its TRACTr platform, in metastatic castration-resistant prostate cancer (mCRPC). The company said the data demonstrate "durable responses and a manageable safety profile," with promising radiographic progression-free survival (rPFS) and deep prostate-specific antigen (PSA) declines in heavily pretreated patients. Durable activity in heavily pretreated mCRPC. As of the October 15, 2025 data cut-off, a total of 109 patients had been treated across the Phase 1a dose-escalation and Phase 1b expansion cohorts. Among RECIST-evaluable patients, 8 of 27 ( | 30%) achieved confirmed or unconfirmed partial responses. In terms of PSA reduction, many patients achieved deep and durable declines. According to the company presentation, >= PSA50 (>= 50% drop) and high fractions of PSA90 / PSA99 reductions were observed in those receiving target doses (>= 2 mg). Radiographic progression-free survival ranged from 7.9 to 8.9 months, including in the group switched to a less-frequent every-two-weeks (Q2W) dosing schedule, a result Janux says compares favorably with existing mCRPC therapeutic benchmarks. Safety remains a key challenge for T-cell engagers in solid tumors, particularly cytokine release syndrome (CRS). Janux reported that CRS events were largely limited to Grades 1 and 2 and mainly occurred in the first treatment cycle. The company has identified a mitigation strategy that kept the safety profile manageable. Based on these findings, Janux sees a Q2W dosing interval as a viable and more convenient regimen for patients, something that could be especially valuable for those with advanced disease. Earlier-line and combination therapy plans. Janux's leadership emphasised the potential of JANX007 not just in late-stage, heavily treated mCRPC, but also earlier in the disease course. "We look forward to evaluating the potential for JANX007 in earlier-line mCRPC, where improved tolerability and durability could have an even greater impact," said CEO David Campbell. The company is now planning further development of JANX007 both as monotherapy and in combination with androgen receptor inhibitors for taxane-naïve mCRPC patients. They are also evaluating use in PARP-inhibitor - refractory patients, potentially accelerating the path to registration if results continue to be supportive. Significance for PSMA-targeted therapies. PSMA-targeting has become a validated approach in prostate cancer, for example, with radioligand therapies. The benchmark is set by Novartis with ^177Lu-PSMA-617 (Pluvicto), a radioligand therapy approved for mCRPC, while Telix Pharmaceuticals: is developing TLX591 (radiolabeled antibody) and TLX591-CDx (imaging agent), and Bayer is also involved in the development of PSMA-targeted alpha therapies. T-cell engagers in this space have historically encountered toxicity or insufficient solid-tumor efficacy. Janux's "tumour-activated" TRACTr design attempts to address these issues by minimizing off-tumor effects and toxicity in healthy tissues. The challenge for Janux in differentiating JANX007 from the competition will now focus on earlier-line disease.
Nicholas Investment Partners LP invests $2.73 million in Janux Therapeutics, Inc. (NASDAQ:JANX).